Université Libre de Bruxelles, Brussels, Belgium, Nuria Kotecki, Christiane Jungels, Frederic Hoerner, Jean-Luc Canon, Benoît Colinet, Olivier de Beaumont, Belgium
Case Report
Long stabilization and disease control with AsiDNATM, a first-in-class DNA Repair Inhibitor in combination with carboplatin with or without paclitaxel in patients with advanced solid tumors: A case report
Author(s): Nuria Kotecki
Chemotherapy and radiotherapy represent the backbone of treatment for many cancers at different stages of the disease.While these treatments have been highly effective, recurrence rate of these cancers remain high, partially due to drug resistance and DNA repair mechanisms. AsiDNATM, a first-in-class oligonucleotide
mimicking double-stranded DNA breaks acts as a decoy agonist to DNA damage response in tumour cells. AsiDNATM was investigated in a phase I dose escalation part of DRIIV-1 study, as single agent (part A of the study) in patients with advanced solid tumors who failed standard anticancer therapy. The drug demonstrated to have a favorable safety and pharmacokinetic profiles, and a robust target engagement was evidenced in tumour biopsies. Part A established the dose of 600 mg as the optimal dose for part B and further clinical development. Currently, AsiDNATM is invest.. View More»